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Abstract:  The routine multidisciplinary management of colon cancer is based mainly on tumor staging, histology, grading
and vascular invasion. In this approach, important individual information derived from molecular characteristics of the tumor
may be missed, especially since significant heterogeneity of molecular aberrations in cancer cells has been observed, and
recognition of every of relationships between them may be of value. K-RAS, C-MYC and C-ERBB2 are protooncogenes taking
part in carcinogenesis and tumor progression in the colon. They influence cell proliferation, differentiation and survival. K-RAS
point mutation, as well as amplification of C-MYC and C-ERBB2 were searched in 84 primary colon adenocarcinomas resected
with curative intent. Multiplex polymerase-chain reaction and restriction fragment length polymorphism were performed to
assess codon 12 K-RAS point mutation. Amplification of C-MYC and C-ERBB2 genes was evaluated by densitometry after
agarose gel separation of the respective multiplex PCR products. No relation was found among mutated and/or amplified genes,
and between searched molecular aberrations and pathoclinical features. In multivariate analysis, nodal status appeared to be
the only independent prognostic indicator. In colon adenocarcinoma, codon 12 K-RAS point mutation and amplification of
C-MYC and C-ERBB2 seem to occur independently in the process of tumor progression. Amplification of C-ERBB2 tends to
associate with more advanced stage of disease. Concomitant occurrence of codon 12 K-RAS mutation, C-MYC and C-ERBB2
amplification was of no prognostic value in respect to survival. 
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Introduction
Colorectal cancer is one of the main causes of cancer
death [16]. In spite of preoperative and perioperative
diagnostics together with the pathomorphologic exami-
nation of specimens resected, the real prognosis in a
particular patient remains still unknown [26, 27]. Re-
cognition of all genetic aberrations responsible for pri-
mary tumor development and dissemination of disease
is the potential tool in detailed diagnosis of real tumor
aggressiveness [19, 37]. Intratumor genetic heteroge-
neity of colorectal adenocarcinoma makes doubtful
treating chosen single genetic aberration as a prognostic
factor in colorectal cancer [8]. Probably the alternative
pathways in colorectal carcinogenesis are responsible
for different course of disease in patients with patho-
clinically similar colorectal tumors. Their recognition
can facilitate the settlement of the correct prognosis and
enable successful prophylaxis and treatment of colorec-
tal cancer [19]. Aside mutation in APC gene, responsible
for FAP (familial adenomatous polyposis)-associated
carcinogenesis, as well as in sporadic colorectal cancer,
aberrations in K-RAS, C-MYC, and C-ERBB2 are among
the most often occurring events in early steps of malig-
nant transformation and in further cancer progression in
colon and rectum [1, 15, 18, 19]. 
K-RAS gene is located on chromosome 12, and en-
codes G protein showing GTPase activity. It takes part
in cell signal transduction, and in the control of cell
survival, proliferation, and differentiation [1, 37].
K-RAS mutations are closely associated with impairing
GTPase activity and leaving G protein in its active form,
what results in uncontrolled and excessive cell prolife-
ration and disturbances in their differentiation [1, 19].
Mutation in codon 12 of K-RAS gene is the most com-
monly observed [2, 4, 38]. Aberrations in RAS contribute
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to neoangiogenesis and to metastatic progression inde-
pendently of proliferative hyperactivity of RAS pro-
teins. Similar effect can be caused by C-ERBB2
overexpression [1, 32]. C-ERBB2 gene is located on
chromosome 17 and encodes the cell membrane
p185HER2 protein [3, 18]. It belongs to type I epithelial
growth factor receptor family of cell surface receptors,
and is responsible for signal transmission required for
normal cell proliferation and differentiation [18, 30].
Among several C-ERBB2 signaling targets is MAP ki-
nase (mitogen activated protein) involved in prolifera-
tion and maturation of numerous cell systems. p185HER2
and G proteins may be the factors of MAP-stimulated
cascade of changes. One of their substrates is C-MYC
protein [18]. In breast cancer, C-ERBB2 amplification
occurs in about 25% of cases [23], what is thought to lead
to p185HER2 overexpression. Consecutive increase in
HER2/neu kinase activity initiates signal transduction re-
sulting in excessive cell proliferation [30]. C-ERBB2 pro-
tein overexpression in colorectal cancer cells does not
always follow the amplification of C-ERBB2 gene [29]. 
Protooncogene C-MYC is located on chromosome 8,
and encodes the transcription factor responsible for cell
proliferation promotion through cell-cycle reentry [17,
33]. This ability determines its contribution to carci-
nogenesis, especially in cases with aberrations in C-
MYC gene. CDK4 seems to be the target gene for the
activity of C-MYC closely connected with cell cycle
regulation and tumorigenesis promotion [17]. Several
reports indicate that genetic alterations of C-MYC on-
cogene play an important role in induction and progres-
sion of breast cancer [13, 34, 40]. Overexpression of
C-MYC protein to some extent correlates with gene
amplification but not all tumors with C-MYC amplifica-
tion display increased level of this oncoprotein and some
tumors reveal C-MYC overexpression without gene am-
plification [9, 13]. In colorectal primary tumors, ampli-
fication of C-MYC is less often observed than overex-
pression of C-MYC protein [24]. There was no correla-
tion noticed between C-MYC amplification and the
amount of C-MYC protein in primary colorectal cancer
[33]. Amplification probably associates with increased
potential of colorectal cancer to distal metastatic pro-
gression [22, 33]. 
In the present study, we analysed the occurrence and
relationship among aberrations in protooncogenes in-
volved in the process of tumor formation, and normally
responsible for cell proliferation and differentiation.
Since relations between overexpression of these genes
are well recognized [15, 18, 19], K-RAS mutation in
codon 12, as well as C-MYC and C-ERBB2 amplification
in the resected colon adenocarcinomas were examined.
These molecular aberrations were then correlated with
the following parameters:  age, gender, tumor location
(right or left colon), pTNM status, histopathology type
according to WHO, tumor differentiation, and survival
time.
Materials and methods 
Patients. Eighty four patients with resectable colon adenocarcinoma
were included. They were operated on with curative intent in five
Gdan´sk hospitals between February 1996 and February 1998. The
patients, 39 females and 45 males were from 33 to 87 years old (mean
64 yrs, median 65 yrs). The minimal follow-up period for living
patients (n=44) was 25 months, and the maximal period was 70
months (mean 59.5 months, median 61.5 months). For the patients
who died (n=40) the minimal follow-up period was 4 months, and
the maximal 58 months (mean 22.7 months, median 20 months). The
median follow-up period for the whole group was 47 months.
Tissue preparation. Two sides of colon were considered; right,
including caecum, ascending colon, hepatic flexure with proximal
2/3 of transverse colon, and left, including distal 1/3 of transverse
colon, spleen flexure, descending colon and sigmoid colon. Imme-
diately after surgery, specimens of tumor tissue were collected,
frozen in the liquid nitrogen and stored at -80˚C until examination at
Table 1. Sequences of PCR primers used in the study
Gene Primer Sequence
C-ERBB2 erb1 5’-CACCTGTGAGGCTTCGAAGCTGCAG-3’
C-ERBB2 erb2 5’-GGATATCCAGGAGGTGCAGGGCTAC-3’
TK* tk1 5’-CTCTGGGAACAACTCTGGGATGAGG-3’
TK tk2 5’-ACTCAGGTGGTCCCAGGAAGTGTGG-3’
C-MYC myc1 5’-CTCGAATTCCTTCCAGATATCCTCGCTG-3’
C-MYC myc2 5’-CACTGCGCGCTGCGCCAGGTTT-3’
TPA** tpa1 5’-CGACAATGACATTGGTAAGAGCTCG-3’
TPA tpa2 5’-ACTTACAGGCCTCATGCTTGCCGTA-3’
K-RAS KR1 5’-ACTGAATATAAACTTGTGGTAGTTGGACCT-3’
K-RAS KR2 5’-TCAAAGAATGGTCCTGGACC-3’
*TK - thymidyne kinase; **TPA - plasminogen tissue activator
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the Department of Molecular Biology, Clinical Biochemistry Divi-
sion, Medical University of Gdan´sk. The material was also assessed
microscopically by two independent pathologists at the Department
of Pathology, Medical University of Gdan´sk. 
DNA extraction. DNA extraction from the tissues examined was
carried out using Genomic DNA Prep Plus kit (A&A Biotechnology,
Poland). The DNA content was measured by light absorption at 260
nm. The purity of DNA was assessed based on the calculated ratio
A260/A280.
Determination of C-MYC and C-ERBB2 amplification. Amplifi-
cation of C-MYC and C-ERBB2 was assessed by semi-quantitative
multiplex PCR assay, which in our hands proved to be useful in
evaluating changes in a template copy number [13, 23]. The reaction
mixture contained 50 mM Tris-HCl, pH 9.0, 20 mM ammonium
sulfate, 100-500 ng of template, 0.50 µM each of 5’ and 3’ primers,
0.25 µM of each dNTP, 2.5 mM MgCl2 and 1 Unit of Tfl DNA
polymerase (Epicentre Technologies). The PCR reaction was per-
formed for 30 cycles of 94˚C (1 min), 65˚C (1 min), 72˚C (2 min)
and 94˚C (1 min), 56˚C (1 min), 72˚C (2 min) for C-MYC and
C-ERBB2 amplification, respectively. The amplification assessment
of C-MYC and C-ERBB2 was performed with the primers described
by Kowara et al. [23]. Tissue plasminogen activator (TPA) and
thymidine kinase (TK) were the reference genes for C-MYC and
C-ERBB2 amplification, respectively. The primers for TPA and TK
amplification assessment were described by Lonn et al. [25]. The
PCR products were separated by agarose gel electrophoresis and the
ethidium bromide-stained bands were quantified with the use of Gel
Doc 2000 system (Bio-Rad) and compared using computer software
Quantity One (Bio-Rad). To produce titration curve of gene ampli-
fication, we used MCF7 and SKBR3 cells with defined C-MYC and
C-ERBB2 gene copy number, respectively. The representative pat-
terns of multiplex PCR are presented in Figure 1. All primers used
were from Integrated DNA Technologies, Inc. (Coralville, IA, USA)
and are presented in Table 1.
Determination of K-RAS mutation. The point mutation of K-RAS
gene in codon 12 was determined by PCR-RFLP. Amplification of
the fragment of K-RAS exon 1 was performed with the KR1 and KR2
primers (Table 1). The KR1 primer has a restriction site for BstNI
(underlined), which includes two first nucleotides in codon 12.
Second restriction site for BstNI (underlined) is within KR2. The
reaction mixture contained 10 mM Tris-HCl, pH 8.3, 50 mM KCl,
1.5 mM MgCl2, 0 .001% gelatin, 100 ng of template, 0.50 µM each
of 5’ and 3’ primers, 0.25 µM of each dNTP, and 0.4 Unit of Ampli
Taq Gold DNA polymerase (Perkin Elmer, Roche, USA). The PCR
reaction was performed for 30 cycles of 95˚C (45 s), 56˚C (30 s),
72˚C (30 s) and final extension at 72˚C for 10 min. Following
amplification, 10 µl of the PCR products were digested for 1 hour by
restriction enzyme BstNI (Sigma Bioscience, USA). Reaction pro-
ducts were separated on 8% polyacrylamide gel (Bio-Rad Labora-
Fig. 2. Analysis of K-RAS point mu-
tation in codon 12 in colon adeno-
carcinoma. A 157 bp fragment of
K-RAS exon 1 was amplified and di-
gested with BstN1 enzyme and sepa-
rated on 8% polyacrylamide gel as
described in Materials and methods.
Lane M, DNA molecular weight mar-
ker; lane 1-4, the digested products of
PCR performed on DNA isolated
from examined tissues; lane 0, the di-
gested products of PCR performed
without the template (negative control
of PCR reaction). 
Fig. 1. Analysis of C-MYC and C-
ERBB2 amplif ication in colon
adenocarcinoma.  A:  PCR analysis
of C-MYC amplification with the
gene for tissue plasminogen activa-
tor (TPA) as a reference gene.
B: PCR analysis of C-ERBB2 ampli-
fication with the gene for thymidine
kinase (TK) as a reference gene.
Lane M, DNA molecular weight
marker; lane 0, product of control
PCR performed without the tem-
plate; lane W, PCR product with
wild DNA isolated from healthy per-
son; lane MC and SK, product of
PCR performed with DNA isolated
from cells with defined C-MYC
(MCF 7) and C-ERBB2 (SKBR 3)
amplification, respectively. The
numbers on the top indicate the pa-
tient’s number. Tissues showing C-
MYC or C-ERBB2 amplification are
marked by asterisk.
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tories, USA), stained with ethidium bromide and visualized using
UV illuminator. The PCR product contains 157 bp. Digestion with
restriction enzyme of the K-RAS fragment amplified on normal
matrix results in obtaining 3 fragments; 14, 29 and 114 bp. Mutation
in codon 12 results in the loss of one of the restriction sites and only
two fragments, 14 and 143 bp, can be obtained (Fig. 2). 
Statistics. Frequency tables and chi-square test were used to compare
categorical variables (p<0.01 for statistically significant differences).
Survival analysis was performed according to Kaplan-Meier method.
Log-rank test and Cox proportional hazard model was used in
univariate and multivariate analysis, respectively (p<0.05 for statis-
tically significant differences). 
Results
Median of survival time reached 58 months according
to absolute survival curve. Table 2 contains data on
frequency of K-RAS point mutation, C-MYC and C-
ERBB2 amplification in relation to each other, and to
pTNM stage, feature pT, nodal status, tumor differentia-
tion, cancer histological type according to WHO, and
tumor location. The p values were based on chi-square
test. K-RAS mutation in codon 12 was observed in 27 of
84 cases (32%). Amplification of C-ERBB2 gene and
C-MYC gene was observed in 16% (13 of 84) of exa-
mined specimens. In the analyzed group of colon adeno-
carcinomas, the occurrence of at least one of searched
gene aberrations was observed in 46 tumors (55%), and
lack of any aberrations in 38 (45%). 
We did not observe statistically significant differen-
ces in the occurrence of examined parameters. The
analysis showed only tendency for more frequent occur-
rence of C-ERBB2 amplification in advanced tumors
(p=0.06). C-MYC amplification occurred more often in
left-sided cancers (7 out of 10; p=0.07). C-MYC ampli-
fication was observed in cases without mutant K-RAS
(11 out of 13 amplified). Similarly, C-ERBB2 amplifi-
cation was also observed in tissues with no point muta-
tion in K-RAS (10 out of 13 amplified). Conversely,
K-RAS was mutated when no amplification in C-ERBB2
(24 out of 27 mutated) or in C-MYC (25 out of 27
mutated) occurred. In only two cases amplification of
C-MYC and C-ERBB2 was diagnosed in the same tumor.
In these cases, no K-RAS mutation was observed. No
C-MYC amplification was noticed among mucinous
type adenocarcinomas. In univariate and multivariate
survival analysis according to Cox proportional hazard
model, only nodal status turned out to be an independent
prognostic factor in our study (p=0.039, Table 3).
Discussion
Molecular and immunohistochemical studies show con-
siderable heterogeneity of genetic aberrations in colo-
rectal cancer [8, 19, 37]. Attention is paid to the
possibility of colorectal cancer development on the basis
of totally different genetic aberrations. Continuous evo-
lution of tumor cells results in creation of neoplasms
pathoclinically similar but possessing totally different
genotype. While various theories of colorectal carci-
nogenesis and tumor progression are discussed, it should
be emphasized that the validity of each of them in
particular case could probably be demonstrated [19]. It
seems that recognition of the sequence of genetic
changes in primary tumor with known progression level
can be a valuable advice in studies on treatment of
colorectal cancer. The knowledge of early events in
carcinogenesis and tumor progression is of particular
value. The aberrations in APC suppressor gene control-
ling β-catenin activity and in CTNNB1 gene encoding
β-catenin are thought to play an important role in tumo-
Table 2. The occurrence of K-RAS, C-MYC, and C-ERBB2 molecular
abnormalities in relation to each other, to tumor stage, degree of
differentiation, WHO type, and tumor location
Examined feature
K-RAS 
mutation
C-ERBB2
amplification
C-MYC 
amplification
yes  no yes  no yes  no
C-ERBB2 
amplification 
  yes
 no
 3  10
24  47
p=0.66
C-MYC 
amplification
  yes
 no
 2  11
25  46
p=0.28
 2   11
11  60
p=0.68
pTNM stage
 I
 II
 III
 IV
 2   7
13  24
10  24
 2   2
p=0.74
 2   7
 2  35
 7  27
 2  2
p=0.06
 3   6
 5  32
 4  30
 1   3
p=0.40
 T1-3
 T4
 9  28
18  29
p=0.26
 5  32
 8  39
p=0.89
 6  31
 7  40
p=0.89
 N0
 N1+2
15  34
12  23
p=0.9
 8  41
 5  30
p=0.96
 8  41
 5  30
p=0.96
Tumor differentiation
 good
 moderate
 poor
12  21
14  29
 1   7
p=0.43
 6  27
 6  37
 1   7
p=0.85
 6  27
 6  37
 1   7
p=0.85
WHO type
 adenocarcinoma
 adenocarcinoma 
  mucinosum
25  51
 2   6
p=1.0
12  64
 1   7
p=1.0
13  63
 0   8
p=0.35
Tumor location
 right
 left
16  24
11  33
p=0.22
 7  33
 6  38
p=0.85
 3  37
10  34
p=0.07
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rigenesis promotion in colorectum [15, 41]. β-catenin,
which is present in almost all steps and in every aspect
of colorectal carcinogenesis, is thought to be one of the
most important molecules in the process of tumorige-
nesis [3, 41]. RAS and ERBB2 are the prooncogenic
factors which release β-catenin, and/or facilitate its
translocation into the cell nucleus [3]. The combination
of TCF-4 with β-catenin contributes to expression of
C-MYC that takes part in carcinogenesis [3, 41]. The
loss of control on β-catenin can contribute to activation
of K-RAS by point mutation [3, 15]. K-RAS, C-ERBB2
and C-MYC genes normally are responsible for proper
cell proliferation, differentiation, and survival [1, 10,
18]. Aberration of their physiological function con-
tributes to carcinogenesis and tumor progression, also in
early phases of these events [3, 15, 41]. 
In our study, only adenocarcinomas located in the
colon were examined, and tumors of rectosigmoid and
rectal regions were excluded from the investigation.
They were mostly advanced cancers (Table 2). The
material was estimated prospectively. In every case re-
section with curative intent was performed. Among pa-
tients with liver metastases, only those with a chance for
cure after liver metastases resection were included in the
study. The frequency of the examined aberrations corre-
sponded with that observed by other authors [1, 2, 5, 11].
It is worth noticing that there was no correlation between
amplification of C-MYC and C-ERBB2 on the one hand
and K-RAS point mutation on the other. It should be
stressed that in 45% of primary tumors (38 cases) none
of the examined genetic aberrations was observed. Our
results seem to support the theory according to which
accumulation of genetic changes does not necessarily
occur during tumor progression. 
In the study of Zhang et al. [42], changes in K-RAS,
and C-ERBB2 genes correlated with histological type of
colorectal cancer:  more frequent K-RAS mutations were
associated with mucinous type of tumors. In spite of
similar percentages of mucinous tumor type in their
series (11%) and in our material (10%), we were not able
to confirm these associations. The large number of pa-
tients in the former study and thus the ability to detect
smaller differences could partially account for this dis-
crepancy.
The prognostic value of K-RAS mutation in colorec-
tal cancer remains controversial. This abnormality was
described to correlate with distant spread and worse
survival [5, 12, 38]. The negative prognostic value of
K-RAS mutation was found in 117 colorectal cancer
patients with over 10 years of follow-up [38] as well as
in 98 colorectal cancer patients with median follow-up
of 21 months [12]. In both studies, codon 12 and 13
mutations were analysed. In another study including 229
patients with colon and sigmo-rectal cancer with 7 years
of follow-up, negative influence of K-RAS mutation on
survival was confined to stage II and not to stage III of
the disease [2]. In the latter work, two thirds of K-RAS
mutations were found in codon 12, and K-RAS mutated
tumors were more frequently observed in patients with
more than 3 metastatic regional lymph nodes. Andreyev
et al. [5] collected data on 3439 patients with colorectal
cancer and found prognostically independent associ-
ation between only one mutation in codon 12 of K-RAS
(glycine to valine) and increased risk of disease recur-
rence and death in patients with Dukes C. They did not
observe such an association in Dukes B patients. In the
present report based on 84 colon adenocarcinomas in a
group of patients with median follow up of 47 months,
occurrence of K-RAS mutation in codon 12 neither af-
fected survival nor was associated with clinical or pa-
thological variables (Table 2). Similar observations
were reported by other authors [4, 6, 24, 28, 39]. 
The finding that C-ERBB2 gene overexpression
in breast cancer associates with worse prognosis
became the beginning for studies on the role of
C-ERBB2 in other neoplasms [14, 18, 21]. It was
demonstrated that C-ERBB2 overexpression in-
creased metastatic potential of malignant cells in some
neoplasms, and that it played a role in resistance to
some cytostatics [18]. In the study involving breast
cancer patients, it was demonstrated that C-ERBB2
overexpression is mainly dependent upon amplifica-
tion of this gene [35]. Press and co-workers [31]
showed that C-ERBB2 amplification negatively in-
fluenced prognosis of women with breast cancer.
Osako et al. presented immunohistochemical analysis
of 146 colorectal tumors, and showed that overex-
pression of C-ERBB2 protein occurred to be an inde-
pendent indicator of poor prognosis [29]. In their
study they found amplification of C-ERBB2 in only 2
out of 44 colorectal cancer cases. According to other
authors, C-ERBB2 protein overexpression correlates ne-
gatively with disease-free survival [20]. In our material, a
trend towards an association with advanced stage and no
other relationship to clinical or pathological parameters
was found for C-ERBB2 amplification (Table 2). 
Table 3. Results of log rank test and multivariate analysis of the
investigated features
Feature Log rank Multivariate
analysis
N0 vs. N1+2 p=0.02 p=0.039
T1-3 vs. T4 p=0.11 p=0.59
M0 vs. M1 p=0.13 p=0.19
Age below and above median p=0.13 p=0.27
C-MYC amplified vs. nonamplified p=0.63 p=0.67
C-ERBB2 amplified vs. nonamplified p=0.71 p=0.88
K-RAS mutated vs. nonmutated p=0.95 p=0.44
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Sikora et al. [36] did not observe amplification of
C-MYC in any from 15 colorectal cancers, finding
mRNA and C-MYC protein in 12 out of 15 investigated
tumors. According to that study, in patients with liver
metastases and with C-MYC protein overexpression in
cancer cells of primary tumors, C-MYC protein overex-
pression was also noticed in metastatic foci. In the study
of Kozma et al. [22], C-MYC amplification was associ-
ated with a high risk of distant but not regional spread.
In our material, only 4 patients relapsed at distant sites
(solitary resectable liver metastases) and thus an appro-
priate analysis of dissemination predictors was im-
possible. Higher frequency of C-MYC amplification in
colorectal cancer metastases in comparison to primary
tumors indicates that the clones of cells harbouring this
abnormality may be selected in the process of dissemi-
nation [33]. According to the cited study, overexpression
of C-MYC protein in metastases did not correlate in any
way with C-MYC gene copy number. The authors con-
cluded that amplification of C-MYC was related to
cancer metastatic progression, and that mechanisms re-
sponsible for gene amplification differed from those
responsible for protein overexpression. Augenlicht and
co-workers [7] found no prognostic impact of C-MYC
amplification in colon cancer. However, they described
a positive predictive value of this abnormality for the
results of chemotherapy in Duke’s stages B2 and C. In
their series, C-MYC amplification was associated with
high tumor grade. According to other authors, C-MYC
amplification is linked to poor prognosis [22, 23]. On the
other hand, in a study of Masramon et al. no association
of C-MYC amplification with clinical or pathological
variables was found except a high correlation with tumor
stage and a trend towards higher frequency of this abnor-
mality in left-sided tumors [24]. In our study we did not
find any correlation between C-MYC amplification and the
studied variables in spite of tendency to more frequent
occurrence of C-MYC amplification in left-sided colon
tumors (p=0.07, Table 2). In a study of Rochlitz et al. [33],
and Masramon et al. [24], neither C-MYC status nor
C-MYC expression level correlated with K-RAS mutation.
Our results indicate that in colon adenocarcinoma, mu-
tation in codon 12 of K-RAS and amplification of C-
ERBB2 and C-MYC seem to occur independently in the
process of tumor progression. Amplification of C-ERBB2
tends to associate with more advanced stage of the
disease. Examination of concomitant codon 12 K-
RAS mutation, C-MYC and C-ERBB2 amplification was
of no prognostic value in respect to survival. According to
multivariate analysis, nodal status appeared to be the only
prognostic indicator for survival.
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